TY  - JOUR
AU  - Plaza-Diaz, Julio
AU  - Solis-Urra, Patricio
AU  - Aragon-Vela, Jeronimo
AU  - Rodriguez-Rodriguez, Fernando
AU  - Olivares-Arancibia, Jorge
AU  - Alvarez-Mercado, Ana I
PY  - 2021
DO  - 10.3390/biomedicines9020145
SN  - 2227-9059
UR  - http://hdl.handle.net/10668/17112
T2  - Biomedicines
AB  - Non-alcoholic fatty liver disease (NAFLD) is an increasing cause of chronic liver illness associated with obesity and metabolic disorders, such as hypertension, dyslipidemia, or type 2 diabetes mellitus. A more severe type of NAFLD, non-alcoholic...
LA  - en
PB  - MDPI AG
KW  - fecal microbiota transplantation
KW  - intestinal permeability
KW  - microbiota
KW  - non-alcoholic steatohepatitis
KW  - physical exercise
KW  - probiotics
KW  - Non-alcoholic Fatty Liver Disease
KW  - Carcinoma, Hepatocellular
KW  - Gastrointestinal Microbiome
KW  - Prebiotics
KW  - Diabetes Mellitus, Type 2
KW  - Global Health
KW  - Liver Neoplasms
KW  - Prognosis
KW  - Obesity
KW  - Diet
KW  - Biomarkers
KW  - Hepatocytes
TI  - Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis.
TY  - research article
VL  - 9
ER  -